Simufilam (PTI-125)
Alzheimer's Disease
Key Facts
About Cassava Sciences
Cassava Sciences is dedicated to advancing innovative therapies for neurodegenerative diseases, with a primary focus on Alzheimer's. Its core technology centers on targeting altered filamin A (FLNA) protein, which the company believes is a key pathological driver of the disease. The company's lead candidate, simufilam, has progressed through Phase 2 and Phase 3 clinical trials, generating significant data and investor attention, though not without controversy. Cassava's strategy is to develop an oral, disease-modifying treatment that could potentially slow or halt the progression of Alzheimer's.
View full company profileAbout Cassava Sciences
Cassava Sciences is dedicated to advancing innovative therapies for neurodegenerative diseases, with a primary focus on Alzheimer's. Its core technology centers on targeting altered filamin A (FLNA) protein, which the company believes is a key pathological driver of the disease. The company's lead candidate, simufilam, has progressed through Phase 2 and Phase 3 clinical trials, generating significant data and investor attention, though not without controversy. Cassava's strategy is to develop an oral, disease-modifying treatment that could potentially slow or halt the progression of Alzheimer's.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |
| Undisclosed Program | uniQure | Preclinical |